Araclon Biotech S.L.   Report issue

For profit Phase 2
Founded: Zaragoza Spain (2015)
Status: Acquired by Grifols (2012)

Organization Overview

First Clinical Trial
2015
NCT03113812
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Araclon Biotech Ltd | Araclon Biotech S.L.

Active Ingredients

Drugs in Phase 2 Trials (1)

abvac40 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Cognitive Dysfunction (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1